Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2291 to 2300 of 2733 total matches.
Systemic Reactions to Imiquimod (Aldara)
The Medical Letter on Drugs and Therapeutics • Nov 08, 2004 (Issue 1195)
have been detected.
1
A physician reader objected,
stating that he had developed fatigue while using the
cream ...
Our May 24, 2004 article on use of the immune response modulator imiquimod (Aldara) for treatment of actinic keratoses stated that no systemic effects have been detected. A physician reader objected, stating that he had developed fatigue while using the cream and had heard from dermatologists that other patients had also reported systemic effects.
Dangerous Drugs
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
reviews of these drugs.
Isotretinoin
1
(Accutane) is a remarkably effective drug
for treatment ...
At a US Senate hearing prompted by the withdrawal of Vioxx, an FDA officer cited 5 drugs as potentially dangerous. It may be useful to revisit Medical Letter reviews of these drugs.
In Brief: Sevelamer-Based Phosphate Binders
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008 (Issue 1280)
form of the anion-exchange resin sevelamer
hydrochloride (Renagel – Genzyme),
1
has been
approved ...
Sevelamer carbonate (Renvela – Genzyme), a buffered form of the anion-exchange resin sevelamer hydrochloride (Renagel – Genzyme),1 has been approved by the FDA for use in patients with chronic kidney disease on dialysis. According to the manufacturer, Renvela will replace Renagel, which has been shown to induce or exacerbate metabolic acidosis in patients on dialysis. Two randomized, crossover studies found the two sevelamer salts equivalent in their ability to lower serum phosphate.2,3 Patients taking the carbonate had higher serum bicarbonate concentrations and fewer gastrointestinal...
In Brief: IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • May 19, 2008 (Issue 1286)
or, after hours, 770-488-7100). Artesunate appears to be more effective than quinine
1
and safer than ...
The drug of choice for patients who require parenteral treatment for malaria is IV artesunate, which is available now from the CDC Malaria Branch (M-F, 8 AM-4:30 PM eastern time, 770-488-7788 or, after hours, 770-488-7100). Artesunate appears to be more effective than quinine1 and safer than quinidine, the other parenteral alternatives in the US. The CDC has supplies of artesunate in Atlanta and in 8 quarantine stations in major airports around the US. It will release the drug for appropriate patients (severe disease or unable to take oral drugs) if it can be supplied as quickly as quinidine,...
In Brief: Intensive Glucose Lowering in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008 (Issue 1289)
%
(actual median HbA
1C
7.5%).The etiology of the higher mortality is unclear.
1
The ADVANCE trial ...
The goal for drug therapy of type 2 diabetes is achieving and maintaining a near-normal glycated hemoglobin (HbA1C) concentration without inducing hypoglycemia; the target has generally been an HbA1C of 6.5-7.0% or lower. Whether treating to this level prevents macrovascular (cardiovascular) events has been unclear. Now, 2 large randomized, double-blind trials in patients with long-standing diabetes and at high risk for cardiovascular disease have found no decrease in macrovascular events with intensive glucose control.The ACCORD trial in about 10,000 patients found that patients intensively...
In Brief: A New Hib Booster
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
. Hiberix can also be
given to children 12-15 months old as a scheduled
booster dose.
1
1. Licensure ...
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old....
Tepotinib (Tepmetko) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024 (Issue 1701)
cancer cells.
Table 1. Pharmacology
Class Kinase inhibitor
Formulation 225 mg tablets
Route Oral ...
The FDA has granted regular approval to the oral
kinase inhibitor tepotinib (Tepmetko – EMD Serono)
for treatment of adults with metastatic non-small
cell lung cancer (NSCLC) harboring mesenchymal-epithelial
transition (MET) exon 14 skipping
alterations. MET exon 14 skipping mutations occur
in 3-4% of NSCLC cases and are associated with
advanced disease and a poor prognosis. Tepotinib
received accelerated approval for the same indication
in 2021 based on initial overall response rates and
duration of response.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e73-4 doi:10.58347/tml.2024.1701f | Show Introduction Hide Introduction
Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
bevacizumab and/or
an anti-programmed death ligand-1 (PD-L1) drug.
Key Points: Tisotumab Vedotin (Tivdak ...
Tisotumab vedotin-tftv (Tivdak – Seagen/Genmab),
a tissue factor-directed antibody and microtubule
inhibitor conjugate, has received full approval from the
FDA for treatment of recurrent or metastatic cervical
cancer that progressed on or after chemotherapy. It
is the first antibody-drug conjugate to be approved
for treatment of cervical cancer. The drug received
accelerated approval from the FDA in 2021 for the
same indication.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e109-10 doi:10.58347/tml.2024.1705g | Show Introduction Hide Introduction
Ribociclib (Kisqali) for Early Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
)-
positive, human epidermal growth factor receptor
2 (HER2)-negative advanced or metastatic breast
cancer,1 ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
ribociclib (Kisqali – Novartis), which was approved by
the FDA in 2017 for use with an aromatase inhibitor
or fulvestrant for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative advanced or metastatic breast
cancer, has now been approved for use with an
aromatase inhibitor for adjuvant treatment of HR-positive,
HER2-negative stage II or III early breast
cancer at high risk of recurrence. Kisqali can be used in
patients with node-positive or node-negative disease.
The CDK 4/6...
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e202-3 doi:10.58347/tml.2024.1717f | Show Introduction Hide Introduction
In Brief: Propofol Revisited
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011 (Issue 1375)
,
such as colonoscopy.
First marketed more than 20 years ago,1 propofol has
a rapid onset of action (patients usually ...
A reader has asked us to review the use of propofol (Diprivan, and others) as a sedative agent for brief procedures, such as colonoscopy.First marketed more than 20 years ago,1 propofol has a rapid onset of action (patients usually lose consciousness in less then one minute) and a short duration of action with a rapid recovery (3-5 minutes) that makes it highly suitable for brief ambulatory procedures. Propofol is now the most commonly used parenteral anesthetic in the US.2 The main problems with its use have been pain on injection and bacterial contamination, both related to its lipid...
